The prostate-specific antigen (PSA) is the main diagnostic biomarker for prostate cancer in clinical use, but it lacks specificity and sensitivity, particularly in low dosage values 1 . 'How to use PSA' remains a current issue, either for diagnosis as a gray zone corresponding to a concentration in serum of 2.5-10 ng/ml which does not allow a clear differentiation to be made between cancer and noncancer 2 or for patient follow-up as analysis of post-operative PSA kinetic parameters can pose considerable challenges for their practical application 3,4 . Alternatively, noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease, e.g. PCA3 in prostate cancer 5,6 and to reveal uncharacterized aspects of tumor biology. Moreover, data from the ENCODE project published in 2012
Introduction
Human endogenous retroviruses (also called HERVs) are spread throughout our genome. They originate from ancestral and independent infections within the germ line, followed by copy-paste propagation processes and leading to multicopy families. Today, they are no more infectious but they occupy 8% of the human genome; as a point of comparison, exons span 2% of the human genome. Data from the ENCODE project published in 2012 showed that different RNA types cover about 62% of the genome, including one third in intergenic regions. Moreover, it appears that the amount of transcriptional regulatory motifs is at least 4.5x higher than the one corresponding to protein-coding exons. HERVs long terminal repeats (LTR) represent a broad range of potential transcriptional regulatory elements, as it is their usual function in infectious retroviruses. Historically, apart from a few loci expressed in the placenta or testis, it was commonly believed that HERV are silent due to epigenetic regulation. Therefore, we have designed a high-density microarray, in Affymetrix format, aiming to optimally characterize individual HERV loci expression, in order to better understand whether they are active, if they drive lncRNA transcription or modulate coding gene expression. This tool dubbed HERV-V2 GeneChip integrates 23,583 HERV probesets and can discriminate 5,573 distinct HERV elements composed of solo LTRs as well as complete and partial proviruses (Figure 2 ). 1 . Initially, PSA was proposed for the diagnosis and treatment of adenocarcinoma of the prostate 11 . It was latter proposed for cancer screening and monitoring the development of the disease 12 . However, there remains a question which is regularly asked: 'how to use PSA'. (i) A gray zone corresponding to a concentration in serum of 2.5-10 ng/ml does not allow a clear difference to be made between cancer and noncancer 2 ; (ii) two large cohort studies enrolling hundreds of thousands of people in Europe and USA failed to come to a clear conclusion about the usefulness of screening in terms of disease specific mortality 13, 14 ; (iii) analysis of post-operative PSA kinetic parameters such as PSA clearance, PSA velocity and doubling time, although simple in theory, can pose considerable challenges in practical application 3, 4 . We may expect that in the coming years, biomarker applications will support a clinical choice between watchful waiting and more or less aggressive treatments depending on tumor phenotype. Concerning the diagnosis rendered by the pathologist, a first limiting factor comes from a 20% false negative diagnosis within prostate biopsies (many cancers are missed by sampling). A second concern deals with the need for an additional biopsy procedure following a negative one, which may present adverse effects.
Radical prostatectomy is currently one of the standard treatments for prostate cancer. It is proposed in healthy patients, aging from 45-65 years, especially in the case of aggressive patterns (Gleason 7 to 10), multifocal tumor or palpable tumor. It is now done in our department using robotic assisted surgery. Because of the growing evidence that molecular markers will have paramount importance in the coming years, we decided to propose to all our patients the possibility of participating in a program for prostate tissue banking. More precisely, the expanding molecular research programs on prostate cancer have resulted in an increasing requirement for access to high quality fresh tumor tissues from prostatectomy specimens. This research, in particular the genomic approaches, required large samples of high DNA/RNA quality. Tumoral and adjacent 'non tumoral' tissues from the same patient are needed. Recommendations for handling and processing radical prostatectomies are designed to preserve pathological features that determine stage and margin status and thereby potential further treatment and prognosis. Any fresh tissue sampling method, therefore, should not compromise subsequent pathological assessments in order to be acceptable to the diagnosis. Macroscopic dissection of the prostate is difficult and great attention needs to be paid to margin tissues and capsular invasion: any dissection for prostate banking should be always conducted by a trained uropathologist according to an agreed protocol. The ethics committee of the medical faculty and the state medical board agreed to these investigations and informed consent was obtained for all patients included in the prostate tissues banking.
Protocol

Surgery
Once removed by the surgeon, keep the prostate on ice until taken in charge of by a pathologist. place it in a RNAse free Eppendorf tube. 10. Take a last 5 µm frozen section for hematoxylin, eosin and Safran and stain it to control the quantity of tumoral cells at the end of the procedure. 11. Put the Eppendorf tube in dry ice and send the sample to the molecular biology laboratory.
Handling of Prostate Tissues
WT-ovation RNA Amplification
Recommendations to perform the amplification steps using the WT-Ovation amplification kit in optimal conditions:
• Run no fewer than eight amplification samples at a time to ensure pipetting precision. Then, account for 1 waste volume when preparing master mixes that require a splitting of the kit into 3 batches of 8 reactions.
• Always keep thawed reagents and reaction tubes on ice unless otherwise instructed.
• Use only a fresh 80% ethanol solution for purification.
• Do not stop at any stage of the protocol. 
sscDNA Purification and Quality Control
1. sscDNA purification. Purify sscDNA using the QIAquik PCR purification kit (Qiagen). Briefly, start by adding 200 µl buffer PB to the 42 µl of amplified cDNA product, mix and load on the column. Then follow the Qiagen procedure. Finally, take a 3 µl (out of 30 µl) aliquot of the sscDNA purified product for quality controls (step 5.2). 2. sscDNA yield and size distribution verification ( Figure 4B) . Check sscDNA yield and size distribution using a Bioanalyzer and a Nanodrop, according to the manufacturer instructions. The size of distribution of amplified cDNA should be typically comprised between 100 and 1,500 bases long with a peak around 600 bases. 
sscDNA Fragmentation
Hybridization to the HERV Chip Microarray
Discussion
Over the last 10 years, most of the attempts for HERV expression measurement have used RT-PCR techniques either to focus on a specific locus [20] [21] [22] [23] [24] or based on the relative conservation of the pol genes to evaluate general trends within HERV genera 25, 26 . Additionally, PCR amplifications using highly degenerated primers coupled with low density microarrays intended to detect and quantify the expression of HERV families 27, 28 . In order to trace the expression of individual locus within a family, approaches based on the PCR amplification of conserved regions combined with subsequent cloning and sequencing enabled transcriptionally active distinct elements of the HML-2 29, 30 or HERV-E4.1 31 families to be identified. Also ending by cloning and sequencing steps, the genome repeat expression monitoring technique aiming to identify promoters among repeats identified active HML-2 specific human solitary LTRs 32, 33 . We successively developed two generations of high-density microarrays dedicated to the analysis of the HERV transcriptome, introducing methodologies suitable for repeated element probe design in order to minimize cross reactions between paralogous elements within a family 34, 35 . The HERV-V2 chip which targets 2,690 distinct proviruses and 2,883 solo LTRs of the HERV-W, HERV-H, HERV-E 4.1, HERV-FRD, HERV-K HML-2 and HERV-K HML-5 families, unveiled the expression of 1,718 HERV loci (Figures 7A and B) in a wide range of tissues 35 , illustrated in this paper by the identification of putative prostate cancer biomarkers. In addition, the use of multiple probesets on a given locus is informative about its transcriptional regulation. First, a U3 negative signal in conjunction with a U5 positive one classifies the LTR as a promoter, and conversely U3 positive and U5 negative signals may reflect a polyadenylation role. We thus identified 326 promoter LTRs in a broad range of tissues 35 and, based on this U3-U5 dichotomous information provided by the array, we proposed and experimentally confirmed for some selected cases that such autonomous transcription was controlled by a methylation dependent epigenetic process 34 (Figure 8) . Second, the detection of signals from e.g. LTR, gag and env independent probesets or issued from probes targeting specific splice junction is informative about the proviral splicing strategy, as illustrated by the ERVWE1/Syncytin1 expression profile in placenta or in tumoral testis 34 . This indicates that the process of HERV specific probe selection is robust enough to support the identification of tissue-associated splicing strategy, as efficiently as for conventional genes 36 ( Figure 8 ).
This method is the first attempt to identify individually HERV locus expression using a custom high density microarray based on Affymetrix technology. The clearly identified advantages of the microarray format to decipher HERV transcriptome consisting of (i) the coordinated exploration of several HERV families and (ii) the simultaneous and independent analysis of the different regions for each locus, e.g. U3 and U5 domains for solo and proviral LTRs, gag or env regions and possible spliced junctions associated with proviral structures, without any a priori on the functionality of the HERV element. Prospects rely upon an improvement of annotations in the microarray-associated biocomputing tools. This should allow one to convert chip signals into biological hypotheses such as whether evidenced active HERVs drive lncRNA transcription or modulate more or less proximal coding gene expression. Indeed, such assumption is supported by recent studies that identified prostate cancer-associated ncRNA transcripts containing components of viral ORFs from the HERV-K endogenous retrovirus family or portions of a viral LTR promoter region 37 , as well as two gene fusion events namely HERV-K22q11-ETV1 and HERV-K17-ETV 38, 39 . Taken transcriptome approach combined with LTR function and splicing strategy identifications may help to decipher the marker versus the trigger components of HERV expression in chronic 40, 41 and infectious diseases 42, 43 .
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